Skip to main content

Efficacy of Autologous Platelet Concentrates and Blood-Derived Products on Complete Healing of Chronic Cutaneous Ulcers: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

In brief

Autologous blood therapies more than doubled odds of chronic ulcer healing

A meta-analysis of nine randomized trials involving 662 people found autologous blood-derived treatments increased the odds of complete healing 2.7-fold compared with standard care, saline dressings, or placebo. The evidence covered several ulcer types, including diabetic foot and venous leg ulcers, but does not establish which treatment works best or whether results apply to other wounds.

Journal
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society (Q1)
Published
1 January 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
María Lourdes Del Río-Solá, Carlos García Padrón, Eva Álvarez García, Clara de la Torre Casaseca, Marina Jiménez-Caja
PMID
43052686
DOI
10.1111/wrr.70225

Why clinicians should know about it

Abstract

Chronic cutaneous ulcers impose substantial clinical and socioeconomic burdens, and conventional care does not always achieve complete closure. Autologous blood-derived therapies, including platelet-rich plasma (PRP), platelet-rich fibrin (PRF/L-PRF), concentrated growth factor (CGF), platelet gel, platelet lysate, and autologous whole blood clot (AWBC), are regenerative adjuncts. We evaluated their effect on complete healing versus standard care, saline dressings, or placebo. We performed a PRISMA 2020 systematic review and meta-analysis of randomised controlled trials. The primary outcome was complete wound healing, analysed as a dichotomous outcome. Odds ratios (ORs) with 95% confidence intervals (CIs) were pooled using a restricted maximum likelihood random-effects model. A shared control group in a three-arm trial was split between comparisons to avoid double counting. Heterogeneity was assessed using Cochran's Q and I2; small-study effects were explored using Egger's test and funnel plots. Eleven trials were included in the systematic review. Ten comparisons from nine trials, representing 662 unique participants, entered the meta-analysis. Autologous blood-derived therapies increased the likelihood of complete healing (OR 2.70, 95% CI 1.65-4.40; p < 0.001), with low heterogeneity (I2 = 20%; Q p = 0.17). The effect remained significant after excluding the AWBC trial (OR 2.40, 95% CI 1.41-4.08; p = 0.001), the CGF trial (OR 2.46, 95% CI 1.54-3.93; p < 0.001), or both (OR 2.09, 95% CI 1.30-3.35; p = 0.002). Egger's test did not indicate significant small-study effects (intercept 1.32; p = 0.16). Autologous blood-derived therapies improved complete healing across the ulcer aetiologies represented. Evidence from one eligible CGF trial does not establish superiority over PRP or PRF. Because the evidence base comprised diabetic foot ulcers, venous and mixed venous-arterial leg ulcers, pressure injuries, leprosy-related neuropathic ulcers, and mixed chronic skin ulcers, findings should not be extrapolated to other wound types. Trial Registration: PROSPERO number: CRD420261430657.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.